EFFECT OF DIANE-35 AND METFORMIN ON LIVER AND KIDNEY OF POLYCYSTIC OVARIAN SYNDROME PATIENTS
Main Article Content
Keywords
Polycystic ovarian syndrome, Diane-35, Metformin, Luteinizing hormone, Follicle stimulating hormone
Abstract
Polycystic ovarian syndrome (PCOS) is one of the most common endocrinal disorders of women of the reproductive age. It is associated with overweight, menstrual irregularities, change in luteinizing, and follicle-stimulating hormone ratio. Diane 35 and Metformin are used for polycystic ovarian syndrome patients to control body mass index, oligomenorrhea, mood changes, acne, and hirsutism levels and increase the chances of conception. The study aims to determine the effects of Diane 35 and metformin on CBC, LFTS, RFTS, L, and LH in the blood of polycystic ovarian syndrome patients. This research was conducted at Sahiwal Medical College, Punjab Pakistan. All the selected patients were screened at The University of Lahore. It was a prospective study in which 50 PCOS women were included by taking their Informed consent. Non-probability convenience sampling technique was used. Group I was the control group, Group II was administered metformin, Group III was administered Diane-35 and Group IIV was treated with Diane-35 and metformin for three months. All groups’ preliminary weight and biochemical tests had been measured. Statistically analyzed results showed that P-value <0.05 and mentioned the age of groups II, III and IV. The mean age of the participants in the group I was 24.00±3.80 years, group II was 25.53±6.41, group III was 29.73±2.37 years and group IV were 29.26±2.84 years. The mean BMI of the participants in the group I was 22.02±3.70, group II was 27.92±7.036 group III was 26.97±6.35 and group IV was 27.08±5.96. In all groups there were 86.7% participants with a history of acne and 2 (13.2%) without a history of acne. There was no significant difference in the mean values of the follicular stimulating hormone and serum luteinizing hormone in different groups. In the group II, there was 1 participant with multiple small follicles in both ovaries, 1 6.7% with multiple cysts, and 60% with PCO. In group II, there was 13.3% participants with a cyst in the ovary and 13.3% with cystic ovaries 6.7% participant with multiple small follicles in both ovaries, 6.7% with multiple cysts, and 46.7% with PCO. In group III there were 26.7% participants with cystic ovaries, 60% with PCO. Our results showed that treating PCOS women with Diane-35 and metformin reduced pathological alterations. Ultimately, PCOS affects women of childbearing age and has negative consequences for fertility and conception by interfering with hormone levels and the timing of ovulation.
References
2. Adelakun, S. A., Ogunlade, B., Aniah, J. A., Akwu, B. P., & Afolabi, M. O. (2024). Excessive Caffeine Intake inhibits steroidogenesis, folliculogenesis and disrupts utero-ovarian tissue histomorphology integrity in experimental rats, and precipitates polycystic ovary syndrome in Sprague-Dawley rats. Food Chemistry Advances, 4, 100678.
3. Bannigida, D. M., Nayak, B. S., & Vijayaraghavan, R. (2020). Insulin resistance and oxidative marker in women with PCOS. Archives of Physiology and Biochemistry, 126(2), 183-186.
4. Biswas, S. (2019). A review on the pharmacological effects of hormonal and antidiabetic drugs in the treatment of Polycystic Ovary Syndrome Brac University].
5. Braun, M. M., Overbeek-Wager, E., & Grumbo, R. J. (2016). Diagnosis and management of endometrial cancer. American family physician, 93(6), 468-474.
6. Dapas, M., Lin, F. T., Nadkarni, G. N., Sisk, R., Legro, R. S., Urbanek, M., Hayes, M. G., & Dunaif, A. (2020). Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. PLoS medicine, 17(6), e1003132.
7. Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270-284.
8. Gao, S. (2018). Data analysis in single-cell transcriptome sequencing. In Computational Systems Biology (pp. 311-326). Springer.
9. Geng, Y., Wang, Z., Xu, X., Sun, X., Dong, X., Luo, Y., & Sun, X. (2023). Extensive therapeutic effects, underlying molecular mechanisms and disease treatment prediction of Metformin: a systematic review. Translational Research.
10. Hu, M., Zhang, Y., Feng, J., Xu, X., Zhang, J., Zhao, W., Guo, X., Li, J., Vestin, E., & Cui, P. (2018). Uterine progesterone signaling is a target for metformin therapy in PCOS-like rats. Journal of Endocrinology, 237(2), 123-137.
11. Huan, L.-Y., Feng, D.-Q., & Ling, B. (2021). Meta-analysis of Kuntai Capsules combined with Diane-35 in treatment of PCOS. Journal of Hainan Medical College, 27(3).
12. Hussein, Y. R., & Soslow, R. A. (2018). Molecular insights into the classification of high-grade endometrial carcinoma. Pathology, 50(2), 151-161.
13. Krishna, D. (2019). Polycystic ovary syndrome. Kamini A Rao, Deepika Krishna. Principles and Practice of Assisted Reproductive Technology. Second edition. Jaypee Brothers Medical Publishers Ltd, 479-522.
14. Liang, X.-y., Lu, C.-l., Su, Y., Jin, X.-y., Wu, M.-l., Lu, Y., Zhou, Y., Zhuang, Z.-x., Luo, C., & Ma, H.-x. (2023). Effectiveness and safety of the combination of Chinese herbal medicine and acupuncture for women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized controlled trials. European Journal of Integrative Medicine, 102291.
15. Liao, M., Li, X., Zhang, H., Zhou, L., Shi, L., Li, W., Shen, R., Peng, G., Zhao, H., & Shao, J. (2024). Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine, 83(1), 227-241.
16. Liu, Y., Wang, Y., Yao, D., Chen, X., Zhang, F., Feng, Y., & Li, X. (2022). Diane-35 and Metformin Induce Autophagy and Apoptosis in Polycystic Ovary Syndrome Women with Early-Stage Endometrial Carcinoma. Genes, 13(1), 131.
17. Ma, R.-L., Deng, Y., Wang, Y.-F., Zhu, S.-Y., Ding, X.-S., & Sun, A.-J. (2021). Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese medical journal, 134(23), 2882-2889.
18. Manna, M. J., Jabur, M. S., Alsabah, A. S., & Baqir, L. S. (2023). A Review on new drugs for treatment of Polycystic Ovarian Syndrome. Karbala Journal of Pharmaceutical Sciences, 1(21).
19. Moghetti, P., & Tosi, F. (2021). Insulin resistance and PCOS: chicken or egg? Journal of Endocrinological Investigation, 44(2), 233-244.
20. Okamura, Y., Saito, F., Takaishi, K., Motohara, T., Honda, R., Ohba, T., & Katabuchi, H. (2017). Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age. Reproductive medicine and biology, 16(1), 67-71.
21. Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M. (2022). Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. International journal of molecular sciences, 23(2), 583.
22. Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020). Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular metabolism, 35, 100937.
23. Sanchez-Rangel, E., & Inzucchi, S. E. (2017). Metformin: clinical use in type 2 diabetes. Diabetologia, 60(9), 1586-1593.
24. Shen, W., Jin, B., Pan, Y., Han, Y., You, T., Zhang, Z., Qu, Y., Liu, S., & Zhang, Y. (2021). The Effects of Traditional Chinese Medicine‐Associated Complementary and Alternative Medicine on Women with Polycystic Ovary Syndrome. Evidence‐Based Complementary and Alternative Medicine, 2021(1), 6619597.
25. Stepto, N., Hiam, D., Gibson-Helm, M., Cassar, S., Harrison, C., Hutchison, S., Joham, A., Canny, B., Moreno-Asso, A., & Strauss, B. (2020). Exercise and insulin resistance in PCOS: muscle insulin signalling and fibrosis. Endocrine connections, 9(4), 346-359.
26. Stepto, N. K., Patten, R. K., Tassone, E. C., Misso, M. L., Brennan, L., Boyle, J., Boyle, R. A., Harrison, C. L., Hirschberg, A. L., & Marsh, K. (2019). Exercise recommendations for women with polycystic ovary syndrome: is the evidence enough? Sports Medicine, 49(8), 1143-1157.
27. Tosi, F., Bonora, E., & Moghetti, P. (2017). Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Human Reproduction, 32(12), 2515-2521.
28. Xiong, F., Xiao, J., Bai, Y., Zhang, Y., Li, Q., & Lishuang, X. (2019). Metformin inhibits estradiol and progesterone-induced decidualization of endometrial stromal cells by regulating expression of progesterone receptor, cytokines and matrix metalloproteinases. Biomedicine & Pharmacotherapy, 109, 1578-1585.
29. Zhang, S., Tu, H., Yao, J., Le, J., Jiang, Z., Tang, Q., Zhang, R., Huo, P., & Lei, X. (2020). Combined use of Diane-35 and metformin improves the ovulation in the PCOS rat model possibly via regulating glycolysis pathway. Reproductive Biology and Endocrinology, 18, 1-11.
30. Zhang, Y., Ho, K., Keaton, J. M., Hartzel, D. N., Day, F., Justice, A. E., Josyula, N. S., Pendergrass, S. A., Davis, L. K., & Edwards, D. R. V. (2020). A genome-wide association study of polycystic ovary syndrome identified from electronic health records. American journal of obstetrics and gynecology, 223(4), 559. e551-559. e521.
31. Zhou, R., Li, S., Liu, J., Wu, H., Yao, G., Sun, Y., Chen, Z.-J., Li, W., & Du, Y. (2020). Up-regulated FHL2 inhibits ovulation through interacting with androgen receptor and ERK1/2 in polycystic ovary syndrome. EBioMedicine, 52, 102635.
32. Ziegenhain, C., Vieth, B., Parekh, S., Reinius, B., Guillaumet-Adkins, A., Smets, M., Leonhardt, H., Heyn, H., Hellmann, I., & Enard, W. (2017). Comparative analysis of single-cell RNA sequencing methods. Molecular cell, 65(4), 631-643. e634.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Aftab Khursheed
Medical Officer in Department of Obstetrics and Gynaecology at Sahiwal Teaching Hospital, Pakistan
Tuba mahmood
House officer at Fatima memorial hospital, Shadman, Lahore, Pakistan.
Shazia Naz
Demonstrator in department of biochemistry at Sahiwal Medical College, Sahiwal, Pakistan.
Shanza Rafi
Demonstrator at Department of Physiology, Multan Medical and Dental college, Multan, Pakistan.
Zunairah Hamayun
Associate Professor in Department of Physiology at Multan Medical and Dental college, Multan, Pakistan
Tayyaba Yasin
Molecular Biology and Biotechnology at The University of Lahore, Lahore, Pakistan.
Hafsa Yasin
Doctor of Physical Therapy at The University of Lahore, Pakistan
Rizwana Dilshad
Associate professor at Swedish College of Pharmacy and Allied Health Sciences Rahim Yar Khan, Pakistan